Lewis Titterton, Jr. Biography and Net Worth

Director of Anixa Biosciences

Mr. Titterton previously served as a Director from August 2010 through August 2016, the last four years of which as Chairman of the Board. He also served as a Director from July 1999 to January 2003. Mr. Titterton's background is in high technology with an emphasis on health care. He is currently the Chairman of the Board of NYMED, Inc., a diversified health services company. Mr. Titterton founded MedE America, Inc. in 1986 and was Chief Executive Officer of Management and Planning Services, Inc. from 1978 to 1986. He holds an MBA from the State University of New York at Albany, and a BA degree from Cornell University.

What is Lewis H. Titterton, Jr.'s net worth?: The estimated net worth of Lewis H. Titterton, Jr. is at least $2.29 million as of July 30th, 2024. Titterton, Jr. owns 890,754 shares of Anixa Biosciences stock worth more than $2,289,238 as of December 27th. This net worth evaluation does not reflect any other assets that Titterton, Jr. may own. Learn More about Lewis H. Titterton, Jr.'s net worth.
How do I contact Lewis H. Titterton, Jr.?: The corporate mailing address for Titterton, Jr. and other Anixa Biosciences executives is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. Anixa Biosciences can also be reached via phone at (408) 708-9808 and via email at [email protected]. Learn More on Lewis H. Titterton, Jr.'s contact information.
Has Lewis H. Titterton, Jr. been buying or selling shares of Anixa Biosciences?: Lewis H. Titterton, Jr. has not been actively trading shares of Anixa Biosciences during the last quarter. Most recently, on Tuesday, July 30th, Lewis H. Titterton, Jr. bought 21,646 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.06 per share, with a total value of $66,236.76. Following the completion of the transaction, the director now directly owns 890,754 shares of the company's stock, valued at $2,725,707.24. Learn More on Lewis H. Titterton, Jr.'s trading history.
Who are Anixa Biosciences' active insiders?: Anixa Biosciences' insider roster includes Arnold Baskies (Director), Emily Gottschalk (Director), Amit Kumar (CEO), and Lewis Titterton, Jr. (Director). Learn More on Anixa Biosciences' active insiders.
Are insiders buying or selling shares of Anixa Biosciences?: In the last year, Anixa Biosciences insiders bought shares 10 times. They purchased a total of 124,378 shares worth more than $368,077.54. The most recent insider tranaction occured on July, 30th when Director Lewis H Titterton Jr bought 21,646 shares worth more than $66,236.76. Insiders at Anixa Biosciences own 22.6% of the company. Learn More about insider trades at Anixa Biosciences.
Information on this page was last updated on 7/30/2024.

Lewis H. Titterton, Jr. Insider Trading History at Anixa Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/30/2024	Buy	21,646	$3.06	$66,236.76	890,754
6/13/2024	Buy	405	$2.70	$1,093.50	856,612
6/10/2024	Buy	330	$2.60	$858.00	849,105
6/7/2024	Buy	10,738	$2.52	$27,059.76	848,775
4/9/2024	Buy	15,009	$3.28	$49,229.52	838,037
4/26/2022	Buy	10,000	$2.79	$27,900.00	988,070
1/11/2022	Buy	2,000	$3.20	$6,400.00
1/7/2022	Buy	11,000	$3.08	$33,880.00
10/29/2021	Buy	18,244	$4.76	$86,841.44
7/26/2021	Buy	30,000	$4.21	$126,300.00	935,826
7/16/2021	Buy	10,000	$4.07	$40,700.00
4/19/2021	Buy	5,000	$3.99	$19,950.00	870,326
9/11/2020	Buy	40,000	$2.08	$83,200.00	1,020,326
6/15/2020	Buy	31,083	$2.35	$73,045.05	955,826
3/13/2020	Buy	5,799	$2.12	$12,293.88	924,743
1/14/2020	Buy	7,400	$3.30	$24,420.00	913,944
9/13/2019	Buy	15,000	$4.10	$61,500.00
4/22/2019	Buy	50,000	$4.09	$204,500.00
10/25/2018	Buy	2,000	$4.05	$8,100.00

Lewis H. Titterton, Jr. Buying and Selling Activity at Anixa Biosciences

Anixa Biosciences Company Overview

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Today's Range

Now: $2.57

$2.55

$2.65

50 Day Range

MA: $3.14

$2.53

$3.97

2 Week Range

Now: $2.57

$2.14

$5.13

Volume

52,945 shs

Average Volume

108,194 shs

Market Capitalization

$82.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol